Latest Share Chat

SUMM.L Share News (SUMM)

SUMM.L Information

There is currently no data for SUMM

Wednesday broker round-up UPDATE

Wed, 03rd Jul 2013 09:16

Aberdeen Asset Management: Bank of America reduces target price from 410p to 360p maintaining an underperform rating.ARM Holdings: UBS upgrades to buy from neutral, keeps target price at 970p.Cineworld: Investec ups target price from 347p to 360p and keeps a buy recommendation. N+1 Singer moves target price from 340p to 357p retaining a hold recommendation.Diageo: Espirito Santo cuts target price from 2280p to 2250p, while leaving its buy recommendation unchanged.Domino's Pizza Group: Canaccord Genuity reduces target price to 550p and downgrades to sell. Numis cuts view to add from buy. Oriel lowers to hold from add.Inchcape: Nomura takes target price from 485p to 500p staying with its neutral rating.Northgate: Goldman Sachs moves target price from 340p to 370p maintaining a neutral rating.Ocado: Jefferies raises target price from 80p to 275p, while keeping its hold recommendation.office2office: Panmure Gordon reduces target price from 120p to 67p and downgrades from buy to hold.Ophir Energy: HSBC Holdings increases target price from 530p to 558p reiterating an overweight rating.Persimmon: Deutsche Bank raises target price from 1060p to 1202p and stays with a hold recommendation. Goldman Sachs ups target price from 1756p to 1811p retaining a strong buy recommendation.PZ Cussons: Canaccord Genuity raises target price to 440p and upgrades from sell to buy.Randgold Resources: Citi increases target price from 3926p to 4491p and maintains a neutral rating.Reckitt Benckiser: Espirito Santo takes target price from 4140p to 4160p, but still recommends selling.SAB Miller: Espirito Santo reduces target price from 3520p to 3360p keeping a neutral rating.Serco Group: HSBC Holdings raises target price from 590p to 670p and upgrades to neutral.Smith (DS): Goldman Sachs lowers target price from 278p to 261p reiterating a neutral rating.Spirent Communications: Investec places both its target price (prev.: 150p) and its buy recommendation under review. Panmure Gordon moves target price from 176p to 166p, while its buy recommendation remains unchanged.Stagecoach: Morgan Stanley ups target price from 310p to 330p and retains an equal-weight rating.Summit Corporation: N+1 Singer shifts target price from 9p to 8.80p keeping a buy recommendation.Super Group: Investec increases target price from 843p to 878p leaving its buy recommendation unaltered.UNITE Group: JP Morgan moves target price from 425p to 450p and keeps an overweight rating.

More News

27 Mar 2019 15:56

Summit Therapeutics Swings To Annual Profit On Sarepta Agreement

LONDON (Alliance News) - Summit Therapeutics PLC on Wednesday said it swung to a profit in its most recent financial year due to the recognition of revenue from its Sarepta Therapeutics Inc pretax

2 Jan 2019 14:08

Polar Capital Holds 6% Summit Therapeutics Stake After Deal (ALLISS)

LONDON (Alliance News) - Summit Therapeutics PLC said Wednesday that Polar Capital LLP holds a 6.47% stake in the drug developer after a transaction on December 21.Polar Capital's the

17 Dec 2018 09:14

Summit Therapeutics proposes $25m fundraiser

(Sharecast News) - Antibiotics developer Summit Therapeutics has entered into a securities purchase agreement for the sale of $25m worth of its US-listed shares in order to extend its cash runway through to January 2020.

11 Dec 2018 16:34

Summit Therapeutics' loss expands on one-off charges

(Sharecast News) - Summit Therapeutics on Tuesday reported that its third quarter loss expanded due to one-off charges, but stated that the company has swung to a profit over the first nine months of the year.

11 Dec 2018 14:31

Summit Therapeutics Third-Quarter Loss Widens Due To One-Off Charges

LONDON (Alliance News) - Summit Therapeutics PLC said Tuesday its third-quarter loss widened sharply due to one-off charges.For the three months ended October 31, the company reported loss

6 Sep 2018 13:55

Summit Therapeutics Discovers New Antibiotics For Superbug Infections

LONDON (Alliance News) - Clinical stage drug company Summit Therapeutics PLC on Thursday said it has discovered multiple new mechanism antibiotics to treat "superbug" antibiotics are at

16 Aug 2018 13:53

Summit Therapeutics Shares Jump As Secures Extra USD12 Million Funding

LONDON (Alliance News) - Summit Therapeutics PLC on Thursday said it secured additional USD12 million from Biomedical Advanced Research & Development Authority, a division of the US Department

20 Apr 2018 13:11

Summit Therapeutics Gets Encouraging Results From Ezutromid Trials

LONDON (Alliance News) - Summit Therapeutics PLC on Friday said new work showed a correlation between a reduction in a muscle damage biomarker and the use of its proposed treatment said analysis a

19 Apr 2018 15:07

Summit Therapeutics Completes Dosing For PhaseOut Clinical Trial

LONDON (Alliance News) - Summit Therapeutics PLC said on Thursday it has completed the ezutromid dosing of patients with Duchenne muscular dystrophy for the full 48-week PhaseOut DMD clinical was

4 Apr 2018 12:53

Tiziana Appoints Leopoldo Zambeletti As Non-Executive Director

LONDON (Alliance News) - Tiziana Life Sciences PLC, a biotechnology company developing drugs for cancer and autoimmune diseases, said Wednesday Leopoldo Zambeletti has joined

27 Mar 2018 12:18

Summit Therapeutics To Raise GBP15 Million Via Share Placing (ALLISS)

LONDON (Alliance News) - Summit Therapeutics PLC said Tuesday that it intends to raise gross proceeds of up to GBP15.0 million via share placing.The to a

14 Mar 2018 17:52

Summit Therapeutics Reports Progress On PhaseOut DMD Trial

LONDON (Alliance News) - Summit Therapeutics PLC at the clinical conference in Arlington highlighted the rigour in the data collection in analysis for its PhaseOut Duchenne 2

1 Feb 2017 16:50

Summit Therapeutics outlines next stage of ridinilazole development

(ShareCast News) - Drug discovery and development company Summit Therapeutics outlined its Phase 3 programme for its novel antibiotic, ridinilazole, following recent regulatory meetings with the US Food and Drug Administration and European Medicines Agency. The AIM-traded firm said, with input from

1 Feb 2017 12:15

Summit Therapeutics Details Phase III Programme For Ridinilazole

18 Jan 2017 12:09

Latest Share Chat

SUMM.L Share News (SUMM)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wednesday broker round-up UPDATE

Login to your account

Quickpicks are a member only feature

Login to your account